Rojas, Laura J.
https://orcid.org/0000-0003-4410-1658
Mayo Clinic
Louis Stokes Cleveland VA Medical Center
Citations 1
ARGONAUT II Study of the In Vitro Activity of Plazomicin against Carbapenemase-Producing Klebsiella pneumoniae
Good, Caryn E., Hujer, Andrea M. , Abdelhamed, Ayman M., Rhoads, Daniel D. , Hujer, Kristine M., Rudin, Susan D., Connolly, Lynn, Krause, Kevin M. , Patel, Robin , Arias, César A. , Kreiswirth, Barry N. , Rojas, Laura J. , D’Souza, Roshan , White, Richard C. , Brinkac, Lauren , Nguyen, Kevin , Singh, Indresh , Fouts, Derrick E. , Group, for the Antibacterial Resistance Leadership, Patel, Robin , Fouts, Derrick E , van Duin, David , Rhoads, Daniel D , Jacobs, Michael R. , Domitrovic, Tatiana , Arias, César A. , Kreiswirth, Barry N , Bonomo, Robert A. , Group, for the Antibacterial Resistance Leadership
Antimicrobial Agents and Chemotherapy | March 5, 2020 | Volume: 64 | Issue: 5 | Pages: No page available
Plazomicin was tested against 697 recently acquired carbapenem-resistant Klebsiella pneumoniae isolates from the Great Lakes region of the United States. Plazomicin MIC 50 and MIC 90 values were 0.25 and 1 mg/liter, respectively; 680 isolates (97.6%) were susceptible (MICs of ≤2 mg/liter), 9 (1.3%) intermediate (MICs of 4 mg/liter), and 8 (1.1%) resistant (MICs of >32 mg/liter). Resistance was associated with rmtF -, rmtB -, or armA -encoded 16S rRNA methyltransferases in all except 1 isolate.